Novo Holdings A/S

In its 13F for Q3 2024 (holdings as of September 30, 2024, filed October 24, 2024), Novo Holdings A/S reported 37 stock positions worth $2.0 billion. Its top holding was VG Morningstar TS MKT ETF-US (VTI) at 14.6% of the portfolio, followed by Tempus AI Class A (TEM, 11.5%) and Brookfield (BN, 9.2%). Compared with Q2 2024, it opened 1 new position, sold out of 2, added to 6 and reduced 7. The biggest buy was Viridian Therapeutics (VRDN, shares +19%) and the biggest sale an exit from Apple (AAPL).

Most Recent 13F
Q2 2026
Location
HELLERUP, G7
CIK
0001388325
Portfolio Value
$2.0B (Q3 2024)
SEC Filing
0000950123-24-009887 ↗ filed Oct 24, 2024

Holdings Value

0$500.0M$1.0B$1.5B$2.0B$2.5B Q1 2024: $1.4B Q1 2024 Q2 2024: $1.9B Q2 2024 Q3 2024: $2.0B $2.0B Q3 2024 Q4 2024: $1.7B Q4 2024 Q1 2025: $1.3B Q1 2025 Q2 2025: $1.4B Q2 2025 Q3 2025: $1.6B Q3 2025 Q4 2025: $1.3B Q4 2025 Q1 2026: $1.2B Q1 2026 Q2 2026: $1.7B Q2 2026

Holdings 37 stocks · $2.0B

VTI VG Morningstar TS MKT ETF-US 14.61% 1,038,550 $294.1M No change
TEM Tempus AI Inc. Class A 11.45% 4,074,419 $230.6M No change
BN Brookfield Corp. 9.22% 3,491,230 $185.6M Reduce -10.0%
EWTX Edgewise Therapeutics Inc. 7.36% 5,549,900 $148.1M Reduce -12.5%
CORT Corcept Therapeutics Inc. 5.54% 2,411,362 $111.6M No change
ASML ASML Holding NV-NY Reg SHS 5.52% 133,336 $111.1M No change
CRM Salesforce Inc. 5.01% 368,560 $100.9M Reduce -23.2%
PCVX Vaxcyte Inc. 4.26% 750,000 $85.7M Reduce -21.1%
MIRM Mirum Pharmaceuticals Inc. 2.91% 1,500,000 $58.5M No change
VRDN Viridian Therapeutics Inc. 2.69% 2,385,000 $54.3M Add +19.3%
BABA Alibaba Group Holding-SP ADR 2.64% 500,827 $53.1M No change
INSM Insmed Inc. 2.63% 724,666 $52.9M Reduce -9.4%
CRNX Crinetics Pharmaceuticals Inc. 2.54% 1,000,000 $51.1M No change
CABO Cable One Inc. 2.06% 118,403 $41.4M No change
AVBP Arrivent Biopharma Inc. 1.76% 1,505,315 $35.4M Add +0.3%
MRUS Merus NV 1.74% 700,000 $35.0M Add +3.7%
BMRN Biomarin Pharmaceutical Inc. 1.71% 490,000 $34.4M No change
CLDX Celldex Therapeutics Inc. 1.63% 963,663 $32.8M Add +13.4%
ALNY Alnylam Pharmaceuticals Inc. 1.62% 118,383 $32.6M No change
PHVS Pharvaris NV 1.59% 1,725,000 $31.9M No change
LANZATECH GLOBAL INC 1.50% 15,814,845 $30.2M No change
BAM Brookfield Asset Mgmt-A 1.47% 627,207 $29.7M No change
CRGX Cargo Therapeutics Inc. 1.41% 1,544,000 $28.5M No change
FOLD Amicus Therapeutics Inc. 1.33% 2,500,000 $26.7M No change
RCKT Rocket Pharmaceuticals Inc. 1.01% 1,100,000 $20.3M No change
ZBIO Zenas Biopharma Inc. 0.97% 1,150,000 $19.5M New
FDMT 4D Molecular Therapeutics Inc. 0.81% 1,500,000 $16.2M Add +7.1%
BPMC Blueprint Medicines Corp. 0.80% 175,000 $16.2M No change
VERV Verve Therapeutics Inc. 0.58% 2,400,000 $11.6M No change
LXEO Lexeo Therapeutics Inc. 0.50% 1,122,581 $10.1M Reduce -22.6%
KYTX Kyverna Therapeutics Inc. 0.45% 1,850,000 $9.0M Add +5.7%
MGX Metagenomi Therapeutics Inc. 0.19% 1,800,000 $3.9M No change
IOBTQ Io Biotech Inc. 0.17% 3,354,449 $3.5M Reduce -24.3%
ABCL Abcellera Biologics Inc. 0.15% 1,126,915 $2.9M No change
MQ Marqeta Inc. 0.11% 441,558 $2.2M No change
DMRA Damora Therapeutics Inc. filed as GALECTO INC 0.06% 99,913 $1.2M No change
SPRO Spero Therapeutics Inc. 0.03% 468,902 $628K No change

Portfolio Sells Q2 2024 → Q3 2024

AAPL Apple Inc. Sold out 0.00% −2.08
CRM Salesforce Inc. Reduce -23.2% 5.01% −1.65
LXEO Lexeo Therapeutics Inc. Reduce -22.6% 0.50% −0.75
MORF Morphic Holding Inc. Sold out 0.00% −0.69
INSM Insmed Inc. Reduce -9.4% 2.63% −0.26
IOBTQ Io Biotech Inc. Reduce -24.3% 0.17% −0.10
PCVX Vaxcyte Inc. Reduce -21.1% 4.26% +0.39
BN Brookfield Corp. Reduce -10.0% 9.22% +0.53
EWTX Edgewise Therapeutics Inc. Reduce -12.5% 7.36% +1.20

Portfolio Buys Q2 2024 → Q3 2024

VRDN Viridian Therapeutics Inc. Add +19.3% 2.69% +1.29
ZBIO Zenas Biopharma Inc. New 0.97% +0.97
AVBP Arrivent Biopharma Inc. Add +0.3% 1.76% +0.26
CLDX Celldex Therapeutics Inc. Add +13.4% 1.63% −0.07
KYTX Kyverna Therapeutics Inc. Add +5.7% 0.45% −0.26
MRUS Merus NV Add +3.7% 1.74% −0.42
FDMT 4D Molecular Therapeutics Inc. Add +7.1% 0.81% −0.78

All Filings

QuarterPositions13F Reported ValueTop Holdings
Q2 2026 25$1.7BEWTX, ASML, COAG, BN, MPLT
Q1 2026 22$1.2BEWTX, BN, ASML, MIRM, MPLT
Q4 2025 24$1.3BBN, EWTX, ASML, MIRM, CRM
Q3 2025 27$1.6BVTI, BN, ASML, MIRM, EWTX
Q2 2025 29$1.4BVTI, BN, ASML, CRM, MIRM
Q1 2025 31$1.3BVTI, BN, EWTX, ASML, CRM
Q4 2024 34$1.7BVTI, BN, TEM, EWTX, ASML
Q3 2024 37$2.0BVTI, TEM, BN, EWTX, CORT
Q2 2024Amended 38$1.9BVTI, BN, TEM, ASML, CRM
Q1 2024 35$1.4BASML, BN, CRM, EPC, CORT